White Paper
Our work in White Paper
-
Key Barriers for Clinical Trials for Alzheimer’s Disease
Alzheimer’s disease (AD) clinical trials are more complicated, costly, and slower than trials for other diseases. Addressing barriers would accelerate the approval of innovative therapies.
Categorized in -
The Value of Treatment for COVID-19
The COVID-19 pandemic has imposed significant and far-reaching health and economic costs. This white paper models and monetizes the health-related benefits of two hypothetical treatments administered either before or after hospitalization; both generate substantial value.
Categorized in -
Taking a Broader View of “Junk Insurance”
Christen Linke Young explains the dangers of junk insurance.
Categorized in -
The Economic Case for Public Investment in Stem Cell Research
Our analysis shows the measure resulted in over 56,000 jobs created and added approximately $10 billion to the state’s economy.
Categorized in -
Making ACA Enrollment More Automatic for the Newly Unemployed
USC-Brooking Schaeffer Initiative researchers lay out strategies to help the newly uninsured transition to Medicaid or the ACA individual market.
Categorized in -
Estimating Potential Spending on COVID-19 Care
Schaeffer Initiative researchers quantify the estimated costs of COVID-19 care in the U.S. in a new report.
Categorized in -
Is the U.S. Ready to Quickly Vaccinate its Population Against COVID-19?
Once a COVID-19 vaccine is developed, achieving universal immunization will require a cohesive, multi-faceted vaccination strategy across the U.S. healthcare system.
Categorized in -
Getting Americans Back to Work (and School) With Pooled Testing
To reopen safely, employers need to identify workers who have active COVID-19 infections and do so at reasonable cost. Pooled testing for the coronavirus is an effective, scalable tool for doing so.
Categorized in -
How Well Could Tax-Based Auto-Enrollment Work?
Auto-enrollment into health insurance coverage is an attractive policy that can drive the U.S. health care system towards universal coverage.
Categorized in -
How Would Sharing Rebates at the Point-Of-Sale Affect Beneficiary Cost-Sharing in Medicare Part D?
If cost-sharing were based on net price it would provide meaningful financial relief to many Part D beneficiaries.
Categorized in